Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature Medicine
Question
Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature Medicine
Direct answer
Peer-reviewed Phase 2b survival data validates the VCN-01 mechanism of action, improving valuation support for TOVX's clinical oncology pipeline. — bullish pressure on TOVX via biotech pipeline derisking via published Phase 2b survival data.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-01
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature Medicine”, revision 1, evidence through 2026-10-01. https://marketontology.com/catalysts/2026-10-01/theriva-biologics-reports-phase-2b-virage-survival-data-in-nature-medicine-e606a5
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| TOVX | ▲Bull | 1–4 weeks | biotech pipeline derisking via published Phase 2b survival data | 66 |
Theriva Biologics Reports Phase 2b VIRAGE Survival Data in Nature Medicine
Peer-reviewed Phase 2b survival data validates the VCN-01 mechanism of action, improving valuation support for TOVX's clinical oncology pipeline. — bullish pressure on TOVX via biotech pipeline derisking via published Phase 2b survival data.
Phase 2b VIRAGE trial publication in Nature Medicine showed improved OS and PFS in pancreatic cancer.
- SourcePhase 2b VIRAGE trial publication in Nature Medicine showed improved OS and PFS in pancreatic cancer.
- TransmissionPeer-reviewed Phase 2b survival data validates the VCN-01 mechanism of action, improving valuation support for TOVX's clinical oncology pipeline.
- SummaryNature Medicine published positive Phase 2b VIRAGE trial results for Theriva's VCN-01. The candidate improved overall survival and progression-free survival in metastatic pancreatic cancer. Data provides clinical proof-of-concept for combination oncolytic adenovirus regimens.
- TOVXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- TOVX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- TOVX price vs. pre-event level
- TOVX volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Theriva Biologics anuncia la publicacion en Nature Medicine de los resultados del ensayo clinico de Fase 2b VIRAGE con VCN-01 en el cancer de pancreas metastasico · press_release · 2026-10-01
Related catalysts
- 2026-10-01Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer DataTOVX
- 2026-10-01Theriva Biologics Reports Positive Phase 2b Pancreatic Cancer Data in NatureTOVX
- 2026-10-01Theriva Biologics Publishes Positive Phase 2b Pancreatic Cancer DataTOVX
- 2026-10-01Theriva Biologics Reports Positive Phase 2b VIRAGE Pancreatic Cancer Data in NatureTOVX
- 2026-10-01Theriva Biologics VIRAGE Phase 2b Data Published in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Publishes Positive VIRAGE Phase 2b Data in Nature MedicineTOVX
- 2026-10-01Theriva Biologics Publishes Phase 2b VIRAGE data in Nature Medicine.TOVX
- 2026-10-01Theriva Biologics Publishes Phase 2b VIRAGE Pancreatic Cancer Data in Nature MedicineTOVX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.